# US 11,433,119 B2 · Methods of treating inflammatory skin disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,433,119 B2
- Document ID: US11433119B2
- Status: Granted
- Kind: B2
- Application number: 16/888,711
- Filed: 2020-05-30
- Published: 2020-10-29
- Granted: 2022-09-06
- Earliest claimed: 2016-11-18
- Assignees: Nepsone Ehf
- Applicants: Nepsone Ehf
- Inventors: Birkir Sveinsson
- Web page: https://patentgrep.com/patent/US11433119B2

## CPC

- A61K 38/225: {Calcitonin gene related peptide}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 38/23: Calcitonins
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for treating, remedying, or preventing inflammatory skin disorders by administering a therapeutically effective dose of at least one an antagonist of a calcitonin gene-related peptide receptor in a pharmaceutically acceptable formulation. The method for treating, remedying, or preventing an inflammatory skin disorder by administering topically and to the pre-psoriatic rim a therapeutically effective dose of at least one an antagonist of a calcitonin gene-related peptide receptor in a pharmaceutically acceptable formulation.

## Claims

### Claim 1

A method of treating psoriasis in an individual in need thereof, the method comprising topically administering at a pre-psoriatic rim of the individual a pharmaceutical composition comprising a therapeutically effective dose of a calcitonin gene-related peptide (“CGRP”) antagonist, wherein the pre-psoriatic rim is a normal looking skin that is substantially adjacent to a psoriatic lesion and characterized by at least one of the following as compared to normal skin: increased CGRP activity, increased blood flow, fewer Langerhans cells, increased dilation of blood vessels, and increased T-cell infiltration, and wherein the CGRP antagonist is a 4-sulfinyl benzamide compound.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is a water-in-oil lotion.

### Claim 3 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises a concentration of the CGRP antagonist of about 0.000001 μg/g to 1 g/g.

### Claim 4 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is applied twice daily at the pre-psoriatic rim.